In a report released today, Kumaraguru Raja from Brookline Capital Markets maintained a Buy rating on Oncternal Therapeutics (ONCT – Research Report), with a price target of $12.00. The company's shares closed last Friday at $1.03, close to its 52-week low of $0.85. According to TipRanks.com, Raja is a 2-star analyst with an average return of 0.7% and a 31.6% success rate. Raja covers the Healthcare sector, focusing on stocks such as Cyclacel Pharmaceuticals, Caladrius Biosciences, and Outlook Therapeutics. Oncternal Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $8.67.
https://www.tipranks.com/news/blurbs/brookline-capital-markets-thinks-oncternal-therapeutics-stock-is-going-to-recover?utm_source=advfn.com&utm_medium=referral
Oncternal Therapeutics (NASDAQ:ONCT)
Gráfico Histórico do Ativo
De Jun 2022 até Jul 2022 Click aqui para mais gráficos Oncternal Therapeutics.
Oncternal Therapeutics (NASDAQ:ONCT)
Gráfico Histórico do Ativo
De Jul 2021 até Jul 2022 Click aqui para mais gráficos Oncternal Therapeutics.